메뉴 건너뛰기




Volumn 15, Issue 2, 2014, Pages 207-215

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation

Author keywords

BCR ABL mutation; Chronic myeloid leukemia; MTOR; Nilotinib; NVP BEZ235; PI3K; Ponatinib resistance

Indexed keywords

BCR-ABL MUTATION; CHRONIC MYELOID LEUKEMIA; MTOR; NILOTINIB; NVP-BEZ235; PI3K; PONATINIB RESISTANCE;

EID: 84891764247     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.26725     Document Type: Article
Times cited : (38)

References (34)
  • 1
    • 0000286732 scopus 로고
    • A minute chromosome in human granulocytic leukemia
    • Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960; 142: 1497
    • (1960) Science , vol.142 , pp. 1497
    • Nowell, P.C.1    Hungerford, D.A.2
  • 2
    • 0033614446 scopus 로고    scopus 로고
    • Chronic myeloid leukemia
    • DOI 10.1056/NEJM199904293401706
    • Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-40; PMID: 10219069; http://dx.doi.org/10.1056/NEJM199904293401706 (Pubitemid 29196596)
    • (1999) New England Journal of Medicine , vol.340 , Issue.17 , pp. 1330-1340
    • Sawyers, C.L.1
  • 3
    • 0031839231 scopus 로고    scopus 로고
    • The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells
    • Tauchi T, Okabe S, Miyazawa K, Ohyashiki K. The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells. Int J Oncol 1998; 12: 1269-76; PMID: 9592185 (Pubitemid 28239935)
    • (1998) International Journal of Oncology , vol.12 , Issue.6 , pp. 1269-1276
    • Tauchi, T.1    Okabe, S.2    Miyazawa, K.3    Ohyashiki, K.4
  • 4
    • 0029063970 scopus 로고
    • Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
    • PMID: 7606002
    • Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-36; PMID: 7606002
    • (1995) Blood , vol.86 , pp. 726-736
    • Skorski, T.1    Kanakaraj, P.2    Nieborowska-Skorska, M.3    Ratajczak, M.Z.4    Wen, S.C.5    Zon, G.6    Gewirtz, A.M.7    Perussia, B.8    Calabretta, B.9
  • 5
    • 0031573141 scopus 로고    scopus 로고
    • Constitutive Activation of JAKs and STATs in BCR-Abl-Expressing Cell Lines and Peripheral Blood Cells Derived from Leukemic Patients
    • Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997; 159: 4720-8; PMID: 9366395 (Pubitemid 127471006)
    • (1997) Journal of Immunology , vol.159 , Issue.10 , pp. 4720-4728
    • Chai, S.K.1    Nichols, G.L.2    Rothman, P.3
  • 6
    • 0035810142 scopus 로고    scopus 로고
    • Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
    • DOI 10.1056/NEJM200104053441402
    • Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42; PMID: 11287973; http://dx.doi.org/10.1056/NEJM200104053441402 (Pubitemid 32267973)
    • (2001) New England Journal of Medicine , vol.344 , Issue.14 , pp. 1038-1042
    • Druker, B.J.1    Sawyers, C.L.2    Kantarjian, H.3    Resta, D.J.4    Reese, S.F.5    Ford, J.M.6    Capdeville, R.7    Talpaz, M.8
  • 8
    • 33947224197 scopus 로고    scopus 로고
    • New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance
    • Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006; 145: 913-23; PMID: 17179059; http://dx.doi.org/10.7326/0003- 4819-145-12-200612190-00008 (Pubitemid 351639967)
    • (2006) Annals of Internal Medicine , vol.145 , Issue.12 , pp. 913-923
    • Kantarjian, H.M.1    Talpaz, M.2    Giles, F.3    O'Brien, S.4    Cortes, J.5
  • 10
    • 73349122639 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
    • European LeukemiaNet PMID: 19884523
    • Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, et al.; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-51; PMID: 19884523; http://dx.doi.org/10.1200/JCO.2009.25.0779
    • (2009) J Clin Oncol , vol.27 , pp. 6041-6051
    • Baccarani, M.1    Cortes, J.2    Pane, F.3    Niederwieser, D.4    Saglio, G.5    Apperley, J.6    Cervantes, F.7    Deininger, M.8    Gratwohl, A.9    Guilhot, F.10
  • 11
    • 73349100015 scopus 로고    scopus 로고
    • The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up
    • PMID: 19729517
    • Garg RJ, Kantarjian H, O'Brien S, Quintás-Cardama A, Faderl S, Estrov Z, Cortes J. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009; 114: 4361-8; PMID: 19729517; http://dx.doi.org/10.1182/blood-2009-05-221531
    • (2009) Blood , vol.114 , pp. 4361-4368
    • Garg, R.J.1    Kantarjian, H.2    O'Brien, S.3    Quintás-Cardama, A.4    Faderl, S.5    Estrov, Z.6    Cortes, J.7
  • 12
    • 65649102301 scopus 로고    scopus 로고
    • Firstline therapy for chronic myeloid leukemia: Past, present, and future
    • PMID: 19306355
    • Pavlovsky C, Kantarjian H, Cortes JE. Firstline therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 2009; 84: 287-93; PMID: 19306355; http://dx.doi.org/10.1002/ajh.21380
    • (2009) Am J Hematol , vol.84 , pp. 287-293
    • Pavlovsky, C.1    Kantarjian, H.2    Cortes, J.E.3
  • 13
    • 79952108609 scopus 로고    scopus 로고
    • AKT signaling in physiology and disease
    • PMID: 20549472
    • Vasudevan KM, Garraway LA. AKT signaling in physiology and disease. Curr Top Microbiol Immunol 2010; 347: 105-33; PMID: 20549472; http://dx.doi.org/10. 1007/82-2010-66
    • (2010) Curr Top Microbiol Immunol , vol.347 , pp. 105-133
    • Vasudevan, K.M.1    Garraway, L.A.2
  • 14
    • 34247116441 scopus 로고    scopus 로고
    • Physiological roles of PKB/Akt isoforms in development and disease
    • DOI 10.1042/BST0350231
    • Dummler B, Hemmings BA. Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans 2007; 35: 231-5; PMID: 17371246; http://dx.doi.org/10.1042/BST0350231 (Pubitemid 46596476)
    • (2007) Biochemical Society Transactions , vol.35 , Issue.2 , pp. 231-235
    • Dummler, B.1    Hemmings, B.A.2
  • 15
    • 2342565881 scopus 로고    scopus 로고
    • Advances in protein kinase B signalling: AKTion on multiple fronts
    • DOI 10.1016/j.tibs.2004.03.006, PII S096800040400074X
    • Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29: 233-42; PMID: 15130559; http://dx.doi.org/10.1016/j.tibs.2004.03.006 (Pubitemid 38591317)
    • (2004) Trends in Biochemical Sciences , vol.29 , Issue.5 , pp. 233-242
    • Brazil, D.P.1    Yang, Z.-Z.2    Hemmings, B.A.3
  • 16
    • 43049131769 scopus 로고    scopus 로고
    • Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
    • PMID: 18166498
    • LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11: 32-50; PMID: 18166498; http://dx.doi.org/10.1016/j.drup. 2007.11.003
    • (2008) Drug Resist Updat , vol.11 , pp. 32-50
    • Lopiccolo, J.1    Blumenthal, G.M.2    Bernstein, W.B.3    Dennis, P.A.4
  • 17
    • 51049109033 scopus 로고    scopus 로고
    • Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
    • PMID: 18606717
    • Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-63; PMID: 18606717; http://dx.doi.org/10.1158/1535-7163.MCT-08-0017
    • (2008) Mol Cancer Ther , vol.7 , pp. 1851-1863
    • Maira, S.M.1    Stauffer, F.2    Brueggen, J.3    Furet, P.4    Schnell, C.5    Fritsch, C.6    Brachmann, S.7    Chène, P.8    De Pover, A.9    Schoemaker, K.10
  • 20
    • 0034722888 scopus 로고    scopus 로고
    • The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
    • DOI 10.1038/sj.onc.1204091
    • Hidalgo M, Rowinsky EK. The rapamycinsensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19: 6680-6; PMID: 11426655; http://dx.doi.org/10.1038/sj.onc.1204091 (Pubitemid 32197708)
    • (2000) Oncogene , vol.19 , Issue.56 , pp. 6680-6686
    • Hidalgo, M.1    Rowinsky, E.K.2
  • 21
    • 53049087363 scopus 로고    scopus 로고
    • Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVPBEZ235 on the tumor vasculature: Implications for clinical imaging
    • PMID: 18701483
    • Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVPBEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008; 68: 6598-607; PMID: 18701483; http://dx.doi.org/10.1158/0008-5472.CAN-08-1044
    • (2008) Cancer Res , vol.68 , pp. 6598-6607
    • Schnell, C.R.1    Stauffer, F.2    Allegrini, P.R.3    O'Reilly, T.4    McSheehy, P.M.5    Dartois, C.6    Stumm, M.7    Cozens, R.8    Littlewood-Evans, A.9    García-Echeverría, C.10
  • 22
    • 51849111524 scopus 로고    scopus 로고
    • NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    • PMID: 18829560
    • Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-30; PMID: 18829560; http://dx.doi.org/10.1158/0008-5472.CAN-08-1385
    • (2008) Cancer Res , vol.68 , pp. 8022-8030
    • Serra, V.1    Markman, B.2    Scaltriti, M.3    Eichhorn, P.J.4    Valero, V.5    Guzman, M.6    Botero, M.L.7    Llonch, E.8    Atzori, F.9    Di Cosimo, S.10
  • 23
    • 57349194139 scopus 로고    scopus 로고
    • Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
    • PMID: 19029981
    • Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-6; PMID: 19029981; http://dx.doi.org/10.1038/nm.1890
    • (2008) Nat Med , vol.14 , pp. 1351-1356
    • Engelman, J.A.1    Chen, L.2    Tan, X.3    Crosby, K.4    Guimaraes, A.R.5    Upadhyay, R.6    Maira, M.7    McNamara, K.8    Perera, S.A.9    Song, Y.10
  • 24
    • 68849091778 scopus 로고    scopus 로고
    • NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
    • PMID: 19671762
    • Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009; 8: 2204-10; PMID: 19671762; http://dx.doi.org/10.1158/1535-7163.MCT-09-0160
    • (2009) Mol Cancer Ther , vol.8 , pp. 2204-2210
    • Liu, T.J.1    Koul, D.2    Lafortune, T.3    Tiao, N.4    Shen, R.J.5    Maira, S.M.6    Garcia-Echevrria, C.7    Yung, W.K.8
  • 25
    • 65949110376 scopus 로고    scopus 로고
    • PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer
    • PMID: 19366795
    • Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009; 69: 3955-62; PMID: 19366795; http://dx.doi.org/10.1158/0008-5472.CAN-08-4450
    • (2009) Cancer Res , vol.69 , pp. 3955-3962
    • Crowder, R.J.1    Phommaly, C.2    Tao, Y.3    Hoog, J.4    Luo, J.5    Perou, C.M.6    Parker, J.S.7    Miller, M.A.8    Huntsman, D.G.9    Lin, L.10
  • 26
    • 67650995912 scopus 로고    scopus 로고
    • Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
    • PMID: 19584292
    • McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009; 69: 5835-42; PMID: 19584292; http://dx.doi.org/10.1158/0008-5472.CAN-08-4285
    • (2009) Cancer Res , vol.69 , pp. 5835-5842
    • McMillin, D.W.1    Ooi, M.2    Delmore, J.3    Negri, J.4    Hayden, P.5    Mitsiades, N.6    Jakubikova, J.7    Maira, S.M.8    Garcia-Echeverria, C.9    Schlossman, R.10
  • 27
    • 51649098950 scopus 로고    scopus 로고
    • The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
    • PMID: 18548093
    • Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008; 22: 1728-36; PMID: 18548093; http://dx.doi.org/10.1038/leu.2008.158
    • (2008) Leukemia , vol.22 , pp. 1728-1736
    • Kojima, K.1    Shimanuki, M.2    Shikami, M.3    Samudio, I.J.4    Ruvolo, V.5    Corn, P.6    Hanaoka, N.7    Konopleva, M.8    Andreeff, M.9    Nakakuma, H.10
  • 29
    • 0037194613 scopus 로고    scopus 로고
    • Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
    • DOI 10.1038/sj.onc.1205724
    • Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 2002; 21: 5868-76; PMID: 12185586; http://dx.doi.org/10.1038/ sj.onc.1205724 (Pubitemid 35007237)
    • (2002) Oncogene , vol.21 , Issue.38 , pp. 5868-5876
    • Klejman, A.1    Rushen, L.2    Morrione, A.3    Slupianek, A.4    Skorski, T.5
  • 32
    • 34247506325 scopus 로고    scopus 로고
    • Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
    • DOI 10.1182/blood-2006-01-015347
    • Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007; 109: 5011-5; PMID: 17303698; http://dx.doi.org/10.1182/blood-2006-01-015347 (Pubitemid 46827801)
    • (2007) Blood , vol.109 , Issue.11 , pp. 5011-5015
    • Ray, A.1    Cowan-Jacob, S.W.2    Manley, P.W.3    Mestan, J.4    Griffin, J.D.5
  • 33
    • 34347334539 scopus 로고    scopus 로고
    • Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis
    • DOI 10.1089/scd.2007.9994
    • Okabe S, Tauchi T, Nakajima A, Sashida G, Gotoh A, Broxmeyer HE, Ohyashiki JH, Ohyashiki K. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev 2007; 16: 503-14; PMID: 17610380; http://dx.doi.org/10.1089/scd.2007.9994 (Pubitemid 47016235)
    • (2007) Stem Cells and Development , vol.16 , Issue.3 , pp. 503-514
    • Okabe, S.1    Tauchi, T.2    Nakajima, A.3    Sashida, G.4    Gotoh, A.5    Broxmeyer, H.E.6    Ohyashiki, J.H.7    Ohyashiki, K.8
  • 34
    • 84867763109 scopus 로고    scopus 로고
    • Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCRABL- positive leukemia cells
    • PMID: 22642671
    • Okabe S, Tauchi T, Tanaka Y, Katagiri S, Ohyashiki K. Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCRABL- positive leukemia cells. Stem Cells Dev 2012; 21: 2939-48; PMID: 22642671; http://dx.doi.org/10.1089/scd.2012.0016
    • (2012) Stem Cells Dev , vol.21 , pp. 2939-2948
    • Okabe, S.1    Tauchi, T.2    Tanaka, Y.3    Katagiri, S.4    Ohyashiki, K.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.